Hsbc Holdings PLC Makes New $2.27 Million Investment in Lantheus Holdings, Inc. $LNTH

Hsbc Holdings PLC acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,539 shares of the medical equipment provider’s stock, valued at approximately $2,273,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. EverSource Wealth Advisors LLC boosted its stake in shares of Lantheus by 190.2% during the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after buying an additional 698 shares during the period. First Trust Advisors LP grew its holdings in shares of Lantheus by 37.4% during the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock worth $5,714,000 after buying an additional 19,008 shares during the last quarter. Baird Financial Group Inc. increased its position in Lantheus by 22.6% in the 2nd quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock valued at $222,000 after acquiring an additional 500 shares during the period. Daiwa Securities Group Inc. increased its position in Lantheus by 88.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock valued at $278,000 after acquiring an additional 1,591 shares during the period. Finally, Osterweis Capital Management Inc. purchased a new stake in Lantheus during the 2nd quarter valued at approximately $36,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. CJS Securities downgraded Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday, August 4th. B. Riley Financial downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Monday, August 17th. Brookline Capital Markets lowered shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. TD Cowen cut shares of Lantheus from a “buy” rating to a “hold” rating and dropped their price objective for the company from $110.00 to $102.50 in a research note on Monday, August 3rd. Finally, William Blair set a $102.50 price objective on shares of Lantheus in a research report on Monday, August 3rd. Four research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $108.11.

Lantheus Stock Performance

Shares of LNTH stock opened at $100.77 on Monday. The business’s fifty day moving average price is $103.74 and its 200 day moving average price is $91.76. Lantheus Holdings, Inc. has a 1-year low of $49.67 and a 1-year high of $111.86. The firm has a market capitalization of $6.58 billion, a PE ratio of 24.34 and a beta of -0.03. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. The company had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.Lantheus’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.57 earnings per share. As a group, sell-side analysts forecast that Lantheus Holdings, Inc. will post 4.48 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.